Literature DB >> 26831702

Colorimetric Detection of the Adenylation Activity in Nonribosomal Peptide Synthetases.

Chitose Maruyama1, Haruka Niikura1, Masahiro Takakuwa1, Hajime Katano1, Yoshimitsu Hamano2.   

Abstract

Nonribosomal peptide synthetases (NRPSs) are multifunctional enzymes consisting of catalytic domains. The substrate specificities of adenylation (A) domains determine the amino-acid building blocks to be incorporated during nonribosomal peptide biosynthesis. The A-domains mediate ATP-dependent activation of amino-acid substrates as aminoacyl-O-AMP with pyrophosphate (PPi) release. Traditionally, the enzymatic activity of the A-domains has been measured by radioactive ATP-[(32)P]-PPi exchange assays with the detection of (32)P-labeled ATP. Recently, we developed a colorimetric assay for the direct detection of PPi as a yellow 18-molybdopyrophosphate anion ([(P2O7)Mo18O54](4-)). [(P2O7)Mo18O54](4-) was further reduced by ascorbic acid to give a more readily distinguishable blue coloration. Here we demonstrate the lab protocols for the colorimetric assay of PPi released in A-domain reactions.

Entities:  

Keywords:  ATP–[32P]-PPi exchange assay; Adenylation domain; Colorimetric assay; Nonribosomal peptide synthetase; Poly anion

Mesh:

Substances:

Year:  2016        PMID: 26831702     DOI: 10.1007/978-1-4939-3375-4_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Structural insights into the substrate-bound condensation domains of non-ribosomal peptide synthetase AmbB.

Authors:  Melissa-Jane Chu Yuan Kee; Sakshibeedu R Bharath; Sheena Wee; Matthew W Bowler; Jayantha Gunaratne; Shenquan Pan; Lianhui Zhang; Haiwei Song
Journal:  Sci Rep       Date:  2022-03-30       Impact factor: 4.379

2.  Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.

Authors:  Liusheng Wu; Yanfeng Zhong; Xiaoya Yu; Dingwang Wu; Pengcheng Xu; Le Lv; Xin Ruan; Qi Liu; Yu Feng; Jixian Liu; Xiaoqiang Li
Journal:  Anticancer Drugs       Date:  2022-08-09       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.